Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZG005 vs Sintilimab with Bevacizumab in Advanced HCC
NCT06558227Phase 2Recruiting
- Sponsor
- Zelgen
- Start
- Oct 2024
- Primary completion
- Sep 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nilvanstomig in hepatocellular carcinoma (HCC), sponsored by Zelgen. Started Oct 2024; status: recruiting.
02
Drugs
nilvanstomig
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06558227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06558227.